← All indications
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Subtype terms (6)
More specific conditions that are subtypes of Neoplasm Metastasis in the MeSH hierarchy.
- Extranodal Extension
6 drugs approved
- Lymphatic Metastasis
8 drugs (5 approved, 3 experimental)
- Neoplasm Micrometastasis
- Neoplasm Seeding
1 drug experimental
- Neoplasms, Unknown Primary
15 drugs (14 approved, 1 experimental)
- Neoplastic Cells, Circulating
27 drugs (25 approved, 2 experimental)
Drugs by status
Approved for this indication (9)
Phase 4 trials (46)
- endostatin
- hydromorphone
- vismodegib
- neostigmine
- oxaliplatin
- capecitabine
- propofol
- furmonertinib
- cetuximab
- enoxaparin
- amphotericin b
- cytarabine
- remifentanil
- oxycodone
- gadobenate
- methadone
- acetylsalicylic acid
- remimazolam
- high-selenium yeast
- bevacizumab
- flumazenil
- trastuzumab
- rocuronium
- letrozole
- gadoxetate disodium
- recombinant adenoviral human p53 gene
- anastrozole
- pamidronate
- bupivacaine
- indocyanine green
- +16 more
Phase 3 trials (166)
- dalteparin
- tamoxifen
- chidamide
- dactinomycin
- xaliproden hydrochloride
- clonidine
- temozolomide
- ropivacaine
- icotinib
- nicotinamide
- lenalidomide
- ketorolac
- methylprednisolone
- topotecan
- atezolizumab
- Raltitrexed
- gemcitabine
- 131i-lipiodol
- inosine
- cyclophosphamide
- cytotoxic t cells
- toripalimab
- eribulin
- oxygen
- leuprolide
- futibatinib
- enzalutamide
- ixabepilone
- methylphenidate
- dendritic cells loaded with glioblastoma
- +136 more
Phase 2 trials (350)
- adagrasib
- ifinatamab deruxtecan
- alendronic acid
- ino-3112
- cadonilimab
- tretinoin
- imiquimod
- vitamin e
- volociximab
- 3bp-227
- rituximab
- paricalcitol
- Gebasaxturev
- nelfinavir
- pik-her2 cell
- retifanlimab
- piflufolastat
- tucatinib
- cemiplimab
- regorafenib
- jmt108
- neratinib maleate
- snk01
- olaparib
- axitinib
- defactinib
- shr-a1811
- nedisertib
- gsk-2636771
- conatumumab
- +320 more
Phase 1 trials (306)
Other trials (36)
- ga-68-dota-toc
- cu64 trastuzumab
- lithium
- thyrotropin alfa
- serum
- hemopoietic stem cell
- ranolazine
- sitagliptin
- anti-thyroglobulin mtcr-transduced autologous peripheral blood lymphocytes
- guanabenz
- dexmedetomidine
- ly900009
- deferasirox
- Silibinin
- 89zr-mpdl-3280a-pet scans
- Nimorazole
- ribavirin
- doxepin
- aminobiphosphonate
- bay94-9392
- magnesium oxide
- pantoprazole
- gadopenteate dimeglumine
- 177 lutetium
- piroxicam
- F 18-fluoroazomycin arabinoside
- fluoromisonidazole
- carbon-11 acetate
- darbepoetin beta
- qh104
- +6 more
Organizations
Organization Involved with Phase 4 Indications (92)
- Dermatologic Cooperative Oncology Group
- University of Chicago
- University of Ottawa
- Daiichi Sankyo
- Mahidol University
- University of Kiel
- University of Ioannina
- AbbVie
- Huazhong University of Science and Technology
- Henry Ford Health System
- Badalona Hospital Germans Trias i Pujol
- Nanjing University
- University of Lyon
- Korea University
- Shandong first medical University
- Kyowa Hakko Kirin
- Capital Medical University
- Bio Products Laboratory
- University of Western Ontario
- Pfizer
- Medical Center Buxtehude
- Advanz Pharma
- Washington University in St. Louis
- Xiamen University
- Qidong Gaitianli Medicines Co., Ltd
- Sichuan Huaxi Hopsital
- Boston University
- Medical Research Council
- University of Orense
- Shantou University
- +62 more
Organization Involved with Phase 3 Indications (229)
- Canadian Institutes of Health Research (CIHR)
- Sanchez Cancer Center
- Stowarzyszenie Przyjacio Chorych Hospicjum
- Complexo Hospitalario Universitario de A Coruña
- Angiochem Inc
- The First People's Hospital of Changzhou
- Monash University
- Bajcsy-Zsilinszky Hospital
- Celgene
- BioMS Technology Corp.
- Arbeitsgruppe Lebermetastasen und Tumoren
- Flinders University
- University of Pennsylvania
- Hallym University
- King Khaled Eye Specialist Hospital
- University of Hamburg
- Eicos Sciences, Inc.
- Ludwig Maximilians University
- Government of Canada
- Centre Jean Bernard
- Eastern Cooperative Oncology Group
- University of London
- Light Sciences Oncology
- Gottfried Wilhelm Leibniz Universität Hannover
- AstraZeneca
- J. W. Goethe University
- Duke University
- University of Sydney
- University of Toulouse
- L'Hospitalet de Llobregat
- +199 more
Organization Involved with Phase 2 Indications (352)
- University of Grenoble
- St. Jude Children's Hospital
- Emory University
- Maastricht University
- Institut Bergonié
- Merck Serono
- University of Cantabria
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie (ARTIC)
- Dalian Medical University
- Gloucester Pharmaceuticals
- Covance
- Centre Paul Strauss
- University of Maryland
- Aju Pharm
- DEKK-TEC, Inc.
- Tohoku University
- Shandong Provincial Hospital
- Endocyte
- Norwegian Cancer Society
- National Institute for Health Research, United Kingdom
- University of Padova
- Reata Pharmaceuticals, Inc.
- MedSIR
- Sanofi-Synthelabo
- Shanghai University
- Kyushu University
- Hyogo Medical University
- Deltanoid Pharmaceuticals
- Oxford BioMedica
- AEterna Zentaris
- +322 more
Organization Involved with Phase 1 Indications (130)
- Revolution Medicines, Inc.
- Mater Adult Hospital
- Copharos
- Clovis Oncology
- Invicro
- Shanghai JMT-Bio Inc.
- Virginia Commonwealth University
- City University of New York
- Calico Life Sciences LLC
- ImmVira Pharma Co. Ltd
- Adagene Inc
- Mersana Therapeutics
- Bavarian Nordic
- Cristal Therapeutics
- Neurocenter of Southern Switzerland, Lugano
- KingMed Diagnostics
- National Center for Complementary and Integrative Health (NCCIH)
- VioQuest Pharmaceuticals
- NantWorks
- Verastem, Inc.
- Quadriga Biosciences, Inc.
- Anza Therapeutics, Inc.
- Reliable Cancer Therapies
- Cancer Immunotherapy Trials Network
- HuaDao (Shanghai) Biomedical Co., Ltd.
- VBL
- Dell'Angelo Hospital, Mestre
- Monteris Medical
- F-star Delta Limited
- Alethia Biotherapeutics
- +100 more
Organization Involved with Other Experimental Indications (21)
- Fondation Apicil
- Harbin Medical University
- Kobe University
- Celator Pharmaceuticals
- Government of Thailand
- Yeshiva University
- University of Kentucky
- King Faisal University
- University of Ferrara
- Department of Defense
- Advocate Healthcare
- Government of France
- Main Line Health
- Tanta University
- NHS Lothian
- King Faisal Specialist Hospital
- VitrOmics BV
- University of California, Irvine
- Northeast Ohio Medical University
- Melbourne Health
- Kumamoto University